Dermbits - Watch short videos of KOLs answering your questions

Conditions & Treatments
Learn from the Experts
Support Your Practice
Conferences & Highlights
Community Resources
Our Expert Network

CME & Education About Us

Loading...

CME & Education About Us

Loading profile...

Conditions & Treatments
Learn from the Experts
Support Your Practice
Conferences & Highlights
Community Resources
Our Expert Network

The leading solutions platform for dermatology professionals to elevate patient care.

Helpful Links

Terms of Service

Editorial & Medical Review Policy

Privacy Policy

Cookie Policy

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2026 dermsquared | All Rights Reserved

Dermbits - Watch short videos of KOLs answering your questions

Dermbits

hero

Dermbits

Welcome to Dermbits! Watch short videos of KOLs answering your questions

What does topical treatment fatigue look like in your patients, and how often do you see it drive dissatisfaction or nonadherence?

Psoriasis

What does topical treatment fatigue look like in your patients, and how often do you see it drive dissatisfaction or nonadherence?

Featuring James Del Rosso, DO

What subtle cues, behavioral or clinical, make you suspect a patient is not satisfied or is overwhelmed by topical regimens, even if they report “doing fine”?

Psoriasis

What subtle cues, behavioral or clinical, make you suspect a patient is not satisfied or is overwhelmed by topical regimens, even if they report “doing fine”?

Featuring James Del Rosso, DO

Are dermatologists sometimes too cautious about systemic therapy in limited BSA disease?

Psoriasis

Are dermatologists sometimes too cautious about systemic therapy in limited BSA disease?

Featuring James Del Rosso, DO

What do you emphasize early on so patients understand how improvement with apremilast may differ from topical treatments?

Psoriasis

What do you emphasize early on so patients understand how improvement with apremilast may differ from topical treatments?

Featuring James Del Rosso, DO

What strategies have you found helpful for minimizing early discontinuation related to gastrointestinal side effects with apremilast?

Psoriasis

What strategies have you found helpful for minimizing early discontinuation related to gastrointestinal side effects with apremilast?

Featuring James Del Rosso, DO

Do you ever use apremilast in combination with topical therapy, and if so, in what scenarios?

Psoriasis

Do you ever use apremilast in combination with topical therapy, and if so, in what scenarios?

Featuring James Del Rosso, DO

When apremilast first launched, how was it positioned, and what do we understand differently now?

Psoriasis

When apremilast first launched, how was it positioned, and what do we understand differently now?

Featuring James Del Rosso, DO

How do you frame quality-of-life impact when requesting coverage for ruxolitinib?

Atopic Dermatitis

How do you frame quality-of-life impact when requesting coverage for ruxolitinib?

Featuring Tina Bhutani-Jacques, MD, MAS

When do bridge programs make the most clinical sense for patients?

Atopic Dermatitis

When do bridge programs make the most clinical sense for patients?

Featuring Tina Bhutani-Jacques, MD, MAS

How do you document treatment goals when requesting newer therapies?

Atopic Dermatitis

How do you document treatment goals when requesting newer therapies?

Featuring Tina Bhutani-Jacques, MD, MAS

How do you document medical necessity when disease severity seems borderline?

Atopic Dermatitis

How do you document medical necessity when disease severity seems borderline?

Featuring Tina Bhutani-Jacques, MD, MAS

What clinical language resonates most with payers during prior authorization review?

Atopic Dermatitis

What clinical language resonates most with payers during prior authorization review?

Featuring Tina Bhutani-Jacques, MD, MAS

How do you document body surface area or lesion burden for ruxolitinib coverage decisions?

Atopic Dermatitis

How do you document body surface area or lesion burden for ruxolitinib coverage decisions?

Featuring Tina Bhutani-Jacques, MD, MAS

When might ruxolitinib cream be appropriate earlier in the treatment pathway?

Atopic Dermatitis

When might ruxolitinib cream be appropriate earlier in the treatment pathway?

Featuring Tina Bhutani-Jacques, MD, MAS

What is the single most meaningful management decision that becomes clearer after genomic testing?

Precision Medicine

What is the single most meaningful management decision that becomes clearer after genomic testing?

Featuring David Cotter, MD, PhD

Where do you think clinicians are most likely to misinterpret or overextend genomic test results?

Precision Medicine

Where do you think clinicians are most likely to misinterpret or overextend genomic test results?

Featuring David Cotter, MD, PhD

What type of patient with atopic dermatitis makes you consider the use of AdvanceAD-Tx?

Precision Medicine

What type of patient with atopic dermatitis makes you consider the use of AdvanceAD-Tx?

Featuring David Cotter, MD, PhD

Where in the treatment journey do you see the AdvanceAD-TX test fitting? Before escalation, after failure, or selectively?

Precision Medicine

Where in the treatment journey do you see the AdvanceAD-TX test fitting? Before escalation, after failure, or selectively?

Featuring David Cotter, MD, PhD

What can AdvanceAD-TX tell you that clinical phenotype alone does not?

Precision Medicine

What can AdvanceAD-TX tell you that clinical phenotype alone does not?

Featuring David Cotter, MD, PhD

How can the AdvanceAD-TX test help dermatologists narrow biologic or JAK inhibitor selection in ambiguous cases?

Precision Medicine

How can the AdvanceAD-TX test help dermatologists narrow biologic or JAK inhibitor selection in ambiguous cases?

Featuring David Cotter, MD, PhD

Has testing with AdvanceAD-TX ever shifted you away from your initial treatment choice?

Precision Medicine

Has testing with AdvanceAD-TX ever shifted you away from your initial treatment choice?

Featuring David Cotter, MD, PhD

Has the DecisionDx Melanoma test influenced your imaging threshold in select patients?

Precision Medicine

Has the DecisionDx Melanoma test influenced your imaging threshold in select patients?

Featuring David Cotter, MD, PhD

How do you approach situations where genomic risk classification from DecisionDx Melanoma and AJCC staging don’t align?

Precision Medicine

How do you approach situations where genomic risk classification from DecisionDx Melanoma and AJCC staging don’t align?

Featuring David Cotter, MD, PhD

How does the DecisionDx-SCC test influence referrals to surgical oncology or radiation oncology?

Precision Medicine

How does the DecisionDx-SCC test influence referrals to surgical oncology or radiation oncology?

Featuring David Cotter, MD, PhD

24 of 939